IP Library Granted Patent US 8,581,045
Granted Patent B2
US 8,581,045 · App. 12/950,833 · Granted Nov 12, 2013

Hypervirulent mutant of

Inventors: Stephen K. Farrand (Seymour, IL); David Michael Barnhart (Champaign, IL)
Assignee: The Board of Trustees of the University of Illinois
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,581,045
App. No.
12/950,833
Granted
Nov 12, 2013
Kind
B2
Abstract

This disclosure relates to a mutant Agrobacterium tumefaciens that is functionally deleted for the atu1060 gene that codes for the cyclic di-GMP synthase Atu1060, as well as methods for its use in transforming plants with desired transgenes. Such bacteria are more virulent than currently used strains of A. tumefaciens , and thus can be used to transform a wider variety of plants, such as plants that are traditionally recalcitrant to such transformation.

Claims (22)

1. An isolated Agrobacterium tumefaciens ( A. tumefaciens ) bacterium, wherein a cyclic di-GMP synthase atu1060 gene is functionally deleted.

2. The isolated A. tumefaciens bacterium of claim 1 , wherein the bacterium is a recombinant bacterium comprising an exogenous nucleic acid molecule inserted into a cyclic di-GMP synthase atu1060 gene of the bacterium, thereby functionally deleting the cyclic di-GMP synthase atu1060 gene.

3. The isolated bacterium of claim 1 , wherein the bacterium is A. tumefaciens strain NTL4, NT1, GV2260, GV3101, GV3122, GV3166, GV3850, ACH5, EHA101, EHA105, or C58.

4. The isolated bacterium of claim 1 , wherein the isolated bacterium induces tumors on a host plant at a minimum infection dose at least 5-fold lower than those required by the same strain of A. tumefaciens bacterium having a functional cyclic di-GMP synthase atu1060 gene.

5. The isolated bacterium of claim 1 , wherein the isolated bacterium attaches to glass slides with at least 4-fold greater efficiency than the same strain of A. tumefaciens bacterium having a functional cyclic di-GMP synthase atu1060 gene.

6. The isolated bacterium of claim 1 , wherein the isolated bacterium demonstrates polar lectin binding with at least 4-fold greater efficiency than the same strain of A. tumefaciens bacterium having a functional cyclic di-GMP synthase atu1060 gene.

7. The isolated bacterium of claim 1 , wherein the functional deletion is achieved by removal of at least a portion of the atu1060 gene.

8. The isolated bacterium of claim 1 , wherein the atu1060 gene in a wild-type A. tumefaciens bacterium encodes a protein having at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO: 1.

9. The isolated bacterium of claim 1 , wherein the atu1060 gene in a wild-type A. tumefaciens bacterium comprises the nucleic acid sequence shown in SEQ ID NO: 2.

10. The isolated bacterium of claim 1 , wherein the bacterium does not comprise a nucleic acid sequence comprising SEQ ID NO: 2.

11. The isolated bacterium of claim 1 , wherein the bacterium does not comprise an amino acid sequence having at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO: 1.

12. The isolated bacterium of claim 1 , further comprising a transgene that provides a benefit to a plant.

13. The isolated bacterium of claim 12 , wherein the transgene is a gene that confers resistance to a pest, drought, or herbicide.

14. A method of transforming a plant, comprising:

contacting a plant cell with the isolated bacterium of claim 1 , under conditions that permit the bacterium to infect the plant cell, thereby transforming the plant.

15. The method of claim 14 , wherein the plant cell is a corn cell, wheat cell, rice cell, soybean cell, alfalfa cell, tomato cell, cotton cell, or canola cell.

16. The isolated bacterium of claim 1 , wherein the bacterium is an A. tumefaciens biovar 1 isolate.

17. The isolated bacterium of claim 16 , wherein the bacterium is A. tumefaciens strain C58.

18. The isolated bacterium of claim 1 , wherein the atu1060 gene in a wild-type A. tumefaciens bacterium encodes a protein having at least 92% sequence identity to the amino acid sequence shown in SEQ ID NO: 1.

19. The isolated bacterium of claim 1 , wherein the bacterium does not comprise an amino acid sequence having at least 92% sequence identity to the amino acid sequence shown in SEQ ID NO: 1.

20. The isolated bacterium of claim 1 , wherein the atu1060 gene in a wild-type A. tumefaciens bacterium comprises a nucleic acid sequence having at least 90% sequence identity to the nucleic acid sequence shown in SEQ ID NO: 2.

21. The isolated bacterium of claim 1 , wherein the bacterium does not comprise a nucleic acid sequence having at least 90% sequence identity to the nucleic acid sequence shown in SEQ ID NO: 2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2010
From: FARRAND, STEPHEN K.; BARNHART, DAVID MICHAEL
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 025481/0410 →
CONFIRMATORY LICENSE Recorded Dec 6, 2010
From: UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025445/0013 →
Continuity (2)
Provisional Application 61263305 · Nov 20, 2009
Related Publication 20110126324A1 · May 26, 2011